In the fast-moving Biopharma world, corporate governance can sometimes be low on the priority list and is sometime viewed as little more than a tick box exercise. As a result, many companies have failed to raise the capital they need to succeed. The CFI.co judging panel were seeking an example of a Biopharma that had used the implementation of high governance standards as an enabler for success. ASIT Biotech have given their corporate governance the same level of attention they give to their science. ASIT have been constantly evolving and refining their governance and have ensured the correct business/academic and executive/non-executive balance that in combination with strong product potential has helped deliver several rounds of funding. This year saw the board call in independent evaluation that will help them further strengthen their governance as they look to bring their breakthrough immunotherapy products to market in the near future. The CFI.co judging panel reflected on ASIT’s constant efforts to ensure the correct level of governance to deliver their innovative technology to market and are pleased to announce ASIT Biotech as winner of the award Best Biopharmaceutical Corporate Governance Belgium 2018.
Nordea Asset Management (NAM) has championed responsible investment for over three decades, beginning in 1988…
SegurCaixa Adeslas, a pre-eminent Spanish health insurance company, has demonstrated a formidable and truly impressive…
Banco BPI's dedication to sustainability is a beacon of proactive environmental and social responsibility. Beyond…
BSE Ltd, formerly known as the Bombay Stock Exchange, is a crucial player in India’s…
TMT Investments Plc, publicly quoted on the AIM market of the London Stock Exchange since…
BNP Paribas Fortis is a key player in the Belgian banking sector with a rich…